Shares of Assertio Holdings ASRT moved higher by 0.9% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 33.33% over the past year to ($0.28), which missed the estimate of ($0.03).
Revenue of $20,617,000 decreased by 63.96% from the same period last year, which missed the estimate of $25,330,000.
Outlook
Assertio Holdings hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Aug 07, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/onwswjoj
Price Action
Company's 52-week high was at $2.94
52-week low: $0.55
Price action over last quarter: Up 16.49%
Company Overview
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.